These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35581573)

  • 1. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K
    BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of POLR3G predicts poor prognosis in transitional cell carcinoma.
    Liu X; Zhang W; Wang H; Lai CH; Xu K; Hu H
    PeerJ; 2020; 8():e10281. PubMed ID: 33194434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
    BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
    Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
    Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLK6 Functions as an Oncogene and Unfavorable Prognostic Factor in Bladder Urothelial Carcinoma.
    Zhao K; Gao M; Lin M
    Dis Markers; 2022; 2022():3373851. PubMed ID: 36193495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
    Huang H; Xu Q; Zhang Y; Zhou Y; Ma K; Luo Y
    Curr Pharm Des; 2023; 29(31):2477-2488. PubMed ID: 37916623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
    Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
    Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma.
    Wang Y; Zhu H; Wang X
    Front Genet; 2022; 13():965100. PubMed ID: 36186448
    [No Abstract]   [Full Text] [Related]  

  • 14. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    Xing P; Jiang Z; Liu Y
    BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Li C; Wan Z; Deng Q; Li Z; Wang Y
    Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
    Li L; Zhang Y; Hu W; Zou F; Ning J; Rao T; Ruan Y; Yu W; Cheng F
    J Cell Mol Med; 2023 Oct; 27(19):2922-2936. PubMed ID: 37480214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification.
    Liu R; Ma J; Zhang Y; Zhou Z
    Front Immunol; 2024; 15():1449251. PubMed ID: 39430746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of
    Lin B; Zhang T; Ye X; Yang H
    Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.